Text Size

Hypertensive Treatment Pattern Survey for Type II Diabetes Mellitus Patients With Complication and Hypertension (CRYSTAL-CO)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00771069
First received: October 9, 2008
Last updated: December 2, 2010
Last verified: December 2010
History of Changes
  Purpose

This study will address the treatment rate and control rate of hypertension, treatment pattern and factors to affect blood pressure control by examining (retrospective) medical records of Type II DM patients with DM related complication and hypertension, among outpatients coming to the Endocrinology Department in 20 general hospital settings nationwide.


Condition
Hypertension

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: A Retrospective, Multi Centre, Non-interventional, Observational Study to Investigate Treatment Pattern of Blood Pressure in the Type II Diabetes Mellitus Patients With DM Related Complication and Hypertension.

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Attainment rate to the target blood pressure. [ Time Frame: After collecting all Patient Record Form. ]

Secondary Outcome Measures:
  • Attainment to the target blood pressure will be investigated according to DM related complications. [ Time Frame: After collecting all Patient Record Form. ]
  • Change in the DBP/SBP value will be investigated according to the DM Complication [ Time Frame: After collecting all Patient Record Form. ]
  • Treatment pattern and factors that affect BP control [ Time Frame: After collecting all Patient Record Form. ]

Estimated Enrollment: 2000
Study Start Date: November 2008
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Type II Diabetes Mellitus patients with Complication and Hypertension

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Type II Diabetes Mellitus patients with Complication and Hypertension

Criteria

Inclusion Criteria:

  • After diagnosed type II DM, patients received treatment for a least 3 years
  • Type II DM patients with hypertension and its complication.
  • Visited out-patients to care center after 1 Jan. 2008

Exclusion Criteria:

  • Secondary hypertension patients
  • Patients not receiving hypertension medication
  • Patients stopping BP medication, by physician's order
  • Patients currently enrolled in other clinical studies
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00771069

Locations
Korea, Republic of
Research Site
Bucheon, Gyeonggi, Korea, Republic of
Research Site
Goyang, Gyeonggi, Korea, Republic of
Research Site
Guri, Gyeonggi, Korea, Republic of
Research Site
Sungnam, Gyeonggi, Korea, Republic of
Research Site
Suwon, Gyeonggi, Korea, Republic of
Research Site
Wonju, Kangwon, Korea, Republic of
Research Site
Jeonju, Keollabuk, Korea, Republic of
Research Site
Busan, Korea, Republic of
Research Site
Deagu, Korea, Republic of
Research Site
Deajeon, Korea, Republic of
Research Site
Incheon, Korea, Republic of
Research Site
Kwangju, Korea, Republic of
Research Site
Seoul, Korea, Republic of
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Joonwoo Bahn Astrazenca Korea
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00771069     History of Changes
Other Study ID Numbers: NIS-CKR-DUM-2008/3
Study First Received: October 9, 2008
Last Updated: December 2, 2010
Health Authority: Korea: Food and Drug Administration

Keywords provided by AstraZeneca:
Hypertension
Type II DM
DM related complication
 JNC7
2007 ESH-ESC guidelines
survey

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Hypertension
Glucose Metabolism Disorders
 Metabolic Diseases
Endocrine System Diseases
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on June 18, 2013